Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,389

This is not a story about how the polar vortex is bad—bad for the human body, bad for public transportation, bad for virtually everything in its path. This is a story about how one being among us is actually taking advantage of the historic cold snap: Cassie the bipedal robot. While humans suffer through the chill, this trunkless pair of ostrich-like legs is braving the frozen grounds of the University of Michigan, for the good of science.

“When we saw the announcement for the polar vortex, we started making plans to see how long we could operate in that kind of weather,” says roboticist Jessy Grizzle. “We were going to tie a scarf on her just so it looked cute, but we decided people would think that was keeping her warm and affecting the experiment, so we didn’t.”

You’ve read your last complimentary article this month. To read the full article, SUBSCRIBE NOW. If you’re already a subscriber, please sign in and and verify your subscription.

Read more

A new report estimates that nearly half of all U.S. adults have some form of heart or blood vessel disease, a medical milestone that’s mostly due to recent guidelines that expanded how many people have high blood pressure.

The American Heart Association said Thursday that more than 121 million adults had cardiovascular disease in 2016. Taking out those with only high blood pressure leaves 24 million, or 9 percent of adults, who have other forms of disease such as heart failure or clogged arteries.

Read more

The bacteria that live in our bodies have a pivotal role in the maintenance of our health, and can influence a range of conditions, such as obesity and cancer. Perhaps the most important role for the community of microorganisms that live in our gut — termed the microbiota, which include bacteria, fungi and archaea — is to aid immune-system development. Writing in Nature, Tanoue et al. report the identification of 11 strains of bacteria that reside in the guts of some healthy humans and that can boost immune responses that fight infection and cancer.

Microorganisms in the human gut can affect immune-system cells. Gut bacterial strains have been discovered that boost immune cells that have cell-killing capacity and that can target cancer and protect against infection. Human gut bacteria boost immune cells that have cell-killing capacity.

Read more

Jan. 10 (UPI) — Scientists have developed a single dose treatment that has shown promise for combating all forms of the Ebola virus, a study says.

The new medication successfully blocked a strain of the deadly virus in nonhuman primates and ferrets, according to a study published Thursday in the journal Cell Host & Microbe.

The drug, a two-antibody combination called MBP134, was successful against several strains of Ebola, including the Zaire strain behind the current months-long outbreak in the Democratic Republic of Congo.

Read more

Hansen’s disease, which is commonly known as leprosy, is among the leading causes of non-traumatic, peripheral neuropathies around the world.

The World Health Organization (WHO) initiated its ‘Leprosy Elimination Project’ during the 1980s with great results, curing more than 14 million cases.

Leprosy is caused by Mycobacterium leprae, with the infection progressing to cause disfiguration of the skin and mucous membranes, as well as progressive and irreversible nerve damage.

Read more

Behold the new black gold. Dark and warm, it oozes water and teems with beneficial properties. It even harbors precious metals.

And boy does it stink.

Call it the excrement economy. Between the rise of fecal transplants and water strained from latrine sludge, the poop market is hot. Besides removing toxic waste, the commodification of crap could mean big bucks, especially in the developing world. Sounds crazy, but look at what happened with used cooking oil — now processed into biofuel instead of dumped into landfills — which went from being worth nothing in the early 2000s to $3.30 a gallon in 2011, according to the Utah Biodiesel Supply.

Read more

Morad said in its infancy, AEBi was essentially “doing what everyone else was doing, trying to discover individual novel peptides for specific cancers.”

But then Morad and his colleague, Dr. Hanan Itzhaki, began attempting to identify why other cancer-killing drugs and treatments didn’t work or eventually failed. And they say they’ve found a way to counter that effect.

Morad said most anti-cancer drugs attack a specific target on or in the cancer cell. “Inhibiting the target usually affects a physiological pathway that promotes cancer. Mutations in the targets – or downstream in their physiological pathways – could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective,” he told The Jerusalem Post.

Read more